March 02, 2021
Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society’s 2021 Annual Meeting
Media
March 01, 2021
CARISMA Therapeutics Completes Series B Financing Totaling $59 Million
March 01, 2021
Nordic Nanovector ASA – Notice of extraordinary general meeting
March 01, 2021
Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients
February 27, 2021
BONESUPPORT’S FDA NOTIFICATION: APPROVAL ON DENOVO PATHWAY FOR CERAMENT G WILL REQUIRE ADDITIONAL DATA AND CLARIFICATIONS
February 26, 2021
FDA approves Oncopeptides’ PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
February 26, 2021
Year-end report 2020
February 25, 2021
Strongbridge Biopharma plc to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call on March 3, 2021
February 23, 2021
Nordic Nanovector ASA – Key information regarding potential repair offering
February 23, 2021
Nordic Nanovector – Private placement successfully completed
